Scott J A, Davidson R N, Moody A H, Grant H R, Felmingham D, Scott G M, Olliaro P, Bryceson A D
Hospital for Tropical Diseases, London, UK.
Trans R Soc Trop Med Hyg. 1992 Nov-Dec;86(6):617-9. doi: 10.1016/0035-9203(92)90151-2.
We report 11 patients with leishmaniasis from different endemic areas, treated in the UK with intravenous aminosidine alone or in combination with other drugs. Clinical and parasitological cures were achieved in all 7 patients from the Mediterranean zone who had visceral disease, with one relapse. Two of 4 patients with cutaneous or mucosal disease were cured; the other 2, from Iraq and Iran, did not respond. Toxic effects were high-tone deafness in 2 patients, one of whom had pre-existing renal impairment, and transient, mild elevation of serum creatinine in 3. Aminosidine is an effective, tolerable and relatively non-toxic alternative to existing antileishmanial drugs for the treatment of visceral leishmaniasis. Further studies will be needed to assess its place in cutaneous and mucosal disease.
我们报告了11例来自不同疫区的利什曼病患者，他们在英国接受了单独静脉注射氨基糖苷或与其他药物联合使用的治疗。来自地中海地区患有内脏疾病的7名患者全部实现了临床和寄生虫学治愈，其中1例复发。4例皮肤或黏膜疾病患者中有2例治愈；另外2例来自伊拉克和伊朗的患者没有反应。毒性作用包括2例患者出现高音调耳聋，其中1例患者原有肾功能损害，3例患者血清肌酐短暂轻度升高。氨基糖苷是治疗内脏利什曼病的一种有效、可耐受且相对无毒的现有抗利什曼药物替代品。需要进一步研究以评估其在皮肤和黏膜疾病中的地位。
